MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Închisă

SectorSănătate

123.73 2.37

Rezumat

Modificarea prețului

24h

Curent

Minim

123.53

Maxim

124.48

Indicatori cheie

By Trading Economics

Venit

-7.9B

1.3B

Vânzări

-616M

10B

P/E

Medie Sector

17.147

39.857

EPS

1.09

Randament dividend

1.74

Marjă de profit

12.792

Angajați

114,000

EBITDA

-324M

2.7B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+17.79% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.74%

2.42%

Următoarele câștiguri

15 oct. 2025

Data viitoare de dividende

15 aug. 2025

Următoarea dată ex-dividende

14 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.9B

230B

Deschiderea anterioară

121.36

Închiderea anterioară

123.73

Sentimentul știrilor

By Acuity

41%

59%

138 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Abbott Laboratories Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 12:10 UTC

Câștiguri

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16 apr. 2025, 16:21 UTC

Câștiguri

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 apr. 2025, 12:14 UTC

Câștiguri

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17 iul. 2025, 13:14 UTC

Câștiguri

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 iul. 2025, 12:16 UTC

Câștiguri

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 iul. 2025, 11:32 UTC

Câștiguri

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 iul. 2025, 11:32 UTC

Câștiguri

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 iul. 2025, 11:31 UTC

Câștiguri

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Sales $11.14B >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Net $1.78B >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q EPS $1.01 >ABT

17 iul. 2025, 09:08 UTC

Acțiuni populare

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1 iul. 2025, 18:41 UTC

Achiziții, Fuziuni, Preluări

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16 apr. 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 apr. 2025, 14:17 UTC

Câștiguri

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 apr. 2025, 11:34 UTC

Câștiguri

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 apr. 2025, 11:33 UTC

Câștiguri

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 apr. 2025, 11:32 UTC

Câștiguri

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 apr. 2025, 11:32 UTC

Câștiguri

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 apr. 2025, 11:31 UTC

Câștiguri

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 apr. 2025, 11:30 UTC

Câștiguri

Abbott Reaffirms Full-Yr Guidance

16 apr. 2025, 11:30 UTC

Câștiguri

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 apr. 2025, 11:30 UTC

Câștiguri

Abbott Labs 1Q Sales $10.36B >ABT

16 apr. 2025, 11:30 UTC

Câștiguri

Abbott Labs 1Q Net $1.33B >ABT

Comparație

Modificare preț

Abbott Laboratories Așteptări

Obiectiv de preț

By TipRanks

17.79% sus

Prognoză pe 12 luni

Medie 145.67 USD  17.79%

Maxim 159 USD

Minim 135 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbott Laboratories - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

16

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

132.82 / 134.43Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

138 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.